Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680295 | 0.88 | L3MBTL3 (0.38) | L3MBTL3L3MBTL1 | |
| SCHEMBL19960784 | 0.80 | L3MBTL3 (0.34) | L3MBTL3L3MBTL1 | |
| SCHEMBL11916119 | 0.79 | SIGMAR1 (0.37) | L3MBTL3L3MBTL1 | |
| SCHEMBL117945 | 0.79 | SIGMAR1 (0.41) | L3MBTL3L3MBTL1 | |
| SCHEMBL15804607 | 0.78 | SIGMAR1 (0.31) | L3MBTL3L3MBTL1 | |
| SCHEMBL18843591 | 0.78 | L3MBTL3 (0.45) | L3MBTL3L3MBTL1 | |
| SCHEMBL1709040 | 0.78 | KDM4E (0.42) | — | |
| SCHEMBL20445361 | 0.78 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1 | |
| SCHEMBL12563384 | 0.77 | L3MBTL3 (0.39) | L3MBTL3L3MBTL1 | |
| SCHEMBL13874479 | 0.77 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | TENOVA PHARMACEUTICALS INC. | 2023-05-25 | — | — | US | disclosed |
| US-10695347-B2 | Pyrimidine derivative and use thereof | HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) | 2020-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695347-B2 | Pyrimidine derivative and use thereof | ALK, DPYD, TYMP | L3MBTL3 1766/4885L3MBTL1 1658/4885 |
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | ERBB2, ALK, ERBB3 | L3MBTL3 3062/4885L3MBTL1 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.